Abstract
Objective: To report about clinical outcome of stereotactic body radiation therapy (SBRT) in the treatment of oligometastatic disease in elderly patients. Methods: Patients with 1-4 inoperable metastases were treated with SBRT. Dose prescription ranged from 40 to 75Gy in 3-8 fractions. SBRT was delivered using the volumetric modulated arc therapy technique with flattening filter-free photon beams. The primary end points were in-field local control (LC) and toxicity. Secondary end points were overall survival (OS) and disease-specific survival (DSS). Results: 82 patients with 111 total metastases were treated. Median age was 79 years. 64 patients (78%) had a single lesion; the remaining patients had 2-4 lesions. 16 (14.4%) lesions were localized in the abdomen, 50 (45.0%) in the liver and 45 (40.5%) in the lungs. Local response was observed for 87 lesions (78.4%) while local progression was observed in 24 lesions (21.6%). Actuarial 1-year LC was 86.8%63.3%. Actuarial 1-year OS was 93.6%62.7%. 2-year findings were 76.3%64.4% and 72.0%65.6%, respectively. Actuarial 1- and 2-year DSS results were 97.5%62.0% and 81.6%64.9%, respectively. Treatment-related Grade 2-3 toxicity was observed in five patients (4.2%); Grade 1 toxicity in seven patients (5.9%) and no toxicity was observed in 85.4% of the cases. Conclusion: SBRT is a safe and effective therapeutic option for the treatment of oligometastatic disease in the elderly with acceptable rates of LC and low treatmentrelated toxicity. Advances in knowledge: The use of SBRT for oligometastatic disease in the elderly can be considered as a valuable approach, particularly for patients with fragile status or refusing other approaches.
| Original language | English |
|---|---|
| Article number | 20150111 |
| Journal | British Journal of Radiology |
| Volume | 88 |
| Issue number | 1053 |
| DOIs | |
| Publication status | Published - Sep 1 2015 |
Fingerprint
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging
- Medicine(all)
Cite this
The role of stereotactic body radiation therapy (SBRT) in the treatment of oligometastatic disease in the elderly. / Scorsetti, Marta; Clerici, Elena; Navarria, Piera; D'Agostino, Giuseppe; Piergallini, Lorenzo; De Rose, Fiorenza; Ascolese, Annamaria; Tozzi, Angelo; Iftode, Cristina; Villa, Elisa; Comito, Tiziana; Franzese, Ciro; Mancosu, Pietro; Tomatis, Stefano; Cozzi, Luca.
In: British Journal of Radiology, Vol. 88, No. 1053, 20150111, 01.09.2015.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The role of stereotactic body radiation therapy (SBRT) in the treatment of oligometastatic disease in the elderly
AU - Scorsetti, Marta
AU - Clerici, Elena
AU - Navarria, Piera
AU - D'Agostino, Giuseppe
AU - Piergallini, Lorenzo
AU - De Rose, Fiorenza
AU - Ascolese, Annamaria
AU - Tozzi, Angelo
AU - Iftode, Cristina
AU - Villa, Elisa
AU - Comito, Tiziana
AU - Franzese, Ciro
AU - Mancosu, Pietro
AU - Tomatis, Stefano
AU - Cozzi, Luca
PY - 2015/9/1
Y1 - 2015/9/1
N2 - Objective: To report about clinical outcome of stereotactic body radiation therapy (SBRT) in the treatment of oligometastatic disease in elderly patients. Methods: Patients with 1-4 inoperable metastases were treated with SBRT. Dose prescription ranged from 40 to 75Gy in 3-8 fractions. SBRT was delivered using the volumetric modulated arc therapy technique with flattening filter-free photon beams. The primary end points were in-field local control (LC) and toxicity. Secondary end points were overall survival (OS) and disease-specific survival (DSS). Results: 82 patients with 111 total metastases were treated. Median age was 79 years. 64 patients (78%) had a single lesion; the remaining patients had 2-4 lesions. 16 (14.4%) lesions were localized in the abdomen, 50 (45.0%) in the liver and 45 (40.5%) in the lungs. Local response was observed for 87 lesions (78.4%) while local progression was observed in 24 lesions (21.6%). Actuarial 1-year LC was 86.8%63.3%. Actuarial 1-year OS was 93.6%62.7%. 2-year findings were 76.3%64.4% and 72.0%65.6%, respectively. Actuarial 1- and 2-year DSS results were 97.5%62.0% and 81.6%64.9%, respectively. Treatment-related Grade 2-3 toxicity was observed in five patients (4.2%); Grade 1 toxicity in seven patients (5.9%) and no toxicity was observed in 85.4% of the cases. Conclusion: SBRT is a safe and effective therapeutic option for the treatment of oligometastatic disease in the elderly with acceptable rates of LC and low treatmentrelated toxicity. Advances in knowledge: The use of SBRT for oligometastatic disease in the elderly can be considered as a valuable approach, particularly for patients with fragile status or refusing other approaches.
AB - Objective: To report about clinical outcome of stereotactic body radiation therapy (SBRT) in the treatment of oligometastatic disease in elderly patients. Methods: Patients with 1-4 inoperable metastases were treated with SBRT. Dose prescription ranged from 40 to 75Gy in 3-8 fractions. SBRT was delivered using the volumetric modulated arc therapy technique with flattening filter-free photon beams. The primary end points were in-field local control (LC) and toxicity. Secondary end points were overall survival (OS) and disease-specific survival (DSS). Results: 82 patients with 111 total metastases were treated. Median age was 79 years. 64 patients (78%) had a single lesion; the remaining patients had 2-4 lesions. 16 (14.4%) lesions were localized in the abdomen, 50 (45.0%) in the liver and 45 (40.5%) in the lungs. Local response was observed for 87 lesions (78.4%) while local progression was observed in 24 lesions (21.6%). Actuarial 1-year LC was 86.8%63.3%. Actuarial 1-year OS was 93.6%62.7%. 2-year findings were 76.3%64.4% and 72.0%65.6%, respectively. Actuarial 1- and 2-year DSS results were 97.5%62.0% and 81.6%64.9%, respectively. Treatment-related Grade 2-3 toxicity was observed in five patients (4.2%); Grade 1 toxicity in seven patients (5.9%) and no toxicity was observed in 85.4% of the cases. Conclusion: SBRT is a safe and effective therapeutic option for the treatment of oligometastatic disease in the elderly with acceptable rates of LC and low treatmentrelated toxicity. Advances in knowledge: The use of SBRT for oligometastatic disease in the elderly can be considered as a valuable approach, particularly for patients with fragile status or refusing other approaches.
UR - http://www.scopus.com/inward/record.url?scp=84941712278&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84941712278&partnerID=8YFLogxK
U2 - 10.1259/bjr.20150111
DO - 10.1259/bjr.20150111
M3 - Article
C2 - 26183933
AN - SCOPUS:84941712278
VL - 88
JO - British Journal of Radiology
JF - British Journal of Radiology
SN - 0007-1285
IS - 1053
M1 - 20150111
ER -